1-4 of 4
Tanja Stankovic, PhD
Close
Sort by
Journal Articles

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

Giles Best, PhD, Anne Gardiner, BSc, Rachel Ibbotson, PhD, Aneela Majid, PhD, Renata Walewska, MD, Belinda Austen, MD, Tanja Stankovic, PhD, Martin Dyer, MD, David Graham Oscier, MD
Journal: Blood
Blood (2006) 108 (11): 2795.
https://doi.org/10.1182/blood.V108.11.2795.2795
Published: 2006
Journal Articles

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

Victoria Weston, PhD, Claire Baker, BSc, Belinda Austen, BMBCh, Malcolm Taylor, PhD, Paul Moss, PhD, Tanja Stankovic, PhD
Journal: Blood
Blood (2006) 108 (11): 2110.
https://doi.org/10.1182/blood.V108.11.2110.2110
Published: 2006
Journal Articles

Identification of ATM Mutations in Multiple Myeloma Tumours.

Belinda Austen, BMBCH, Maria Podinovskaia, BSc, Jane Starcynski, PhD, Giancarlo Barone, BSc, Anne Reiman, BM, Phil Byrd, PhD, Guy Pratt, PhD, Malcolm Taylor, PhD, Tanja Stankovic, PhD
Journal: Blood
Blood (2005) 106 (11): 1562.
https://doi.org/10.1182/blood.V106.11.1562.1562
Published: 2005
Journal Articles

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Belinda Austen, MRCP, Christopher Fegan, MD, MRCP, MRCPath, Paul Moss, Phd,MRCP,MRCPath, Tanja Stankovic, Phd
Journal: Blood
Blood (2004) 104 (11): 774.
https://doi.org/10.1182/blood.V104.11.774.774
Published: 2004